June 7, 2020 / 11:51 AM / a month ago

BRIEF-Alnylam Presents Positive Phase 3 Results From ILLUMINATE-A Study Of Lumasiran

June 7 (Reuters) - Alnylam Pharmaceuticals Inc:

* ALNYLAM PRESENTS POSITIVE PHASE 3 RESULTS FROM ILLUMINATE-A STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1

* ALNYLAM-LUMASIRAN MET PRIMARY EFFICACY ENDPOINT OF 24-HOUR URINARY OXALATE REDUCTION FROM MONTH 3 TO 6 RELATIVE TO PLACEBO,ALL TESTED SECONDARY ENDPOINTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below